Complications in community acquired pneumonia: magnitude of problem, risk factors, and management in pediatric age

Expert Rev Anti Infect Ther. 2022 Jan;20(1):45-51. doi: 10.1080/14787210.2021.1927710. Epub 2021 May 21.

Abstract

Introduction: In the last decades, the large use of several effective vaccines has dramatically reduced the incidence of community acquired pneumonia (CAP) in infants and children. Moreover, the availability of new antibiotics effective against emerging resistant strains of bacteria has greatly improved the early and long-term prognosis of this disease.

Areas covered: The aim of this manuscript is to evaluate the burden of complicated CAP in pediatric age and to discuss its appropriate management.

Expert opinion: Complicated CAP remains a problem for children in industrialized and developing countries. A larger use of lung ultrasonography (US) as first diagnostic approach could significantly improve early identification of cases at higher risk of complications. Difficult to solve, is the problem of the use of an antibiotic therapy able to assure adequate control in all the CAP cases, including those at high risk of or with already established complications. All these findings reveal that control of the incidence of complicated CAP remains difficult and will not be significantly changed in the next few years. Any attempt to improve complicated CAP management must be made. Consensus documents on better definition of the use of corticosteroids, fibrinolytic agents, and interventional procedures (including surgery) can allow us to reach this goal.

Keywords: Antibiotics; Staphylococcus aureus; community-acquired pneumonia; lung ultrasonography; vaccine.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Community-Acquired Infections* / diagnosis
  • Community-Acquired Infections* / drug therapy
  • Community-Acquired Infections* / epidemiology
  • Humans
  • Infant
  • Pneumonia* / diagnostic imaging
  • Pneumonia* / drug therapy
  • Pneumonia* / epidemiology
  • Prognosis
  • Risk Factors

Substances

  • Anti-Bacterial Agents